company background image
ALIN

IntegraGen ENXTPA:ALINT Stock Report

Last Price

€1.09

Market Cap

€7.3m

7D

4.3%

1Y

-41.4%

Updated

27 May, 2022

Data

Company Financials
ALINT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance3/6
Financial Health4/6
Dividends0/6

ALINT Stock Overview

IntegraGen SA provides human genome analysis services for academic researcher and life sciences companies in France.

IntegraGen Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for IntegraGen
Historical stock prices
Current Share Price€1.09
52 Week High€2.04
52 Week Low€0.86
Beta0.26
1 Month Change-7.23%
3 Month Change0.18%
1 Year Change-41.40%
3 Year Change-18.96%
5 Year Change-64.84%
Change since IPO-88.00%

Recent News & Updates

Shareholder Returns

ALINTFR BiotechsFR Market
7D4.3%1.4%-1.1%
1Y-41.4%-41.6%-5.9%

Return vs Industry: ALINT matched the French Biotechs industry which returned -41.6% over the past year.

Return vs Market: ALINT underperformed the French Market which returned -5.9% over the past year.

Price Volatility

Is ALINT's price volatile compared to industry and market?
ALINT volatility
ALINT Average Weekly Movement9.6%
Biotechs Industry Average Movement8.7%
Market Average Movement5.9%
10% most volatile stocks in FR Market10.0%
10% least volatile stocks in FR Market3.4%

Stable Share Price: ALINT is more volatile than 75% of French stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: ALINT's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of French stocks.

About the Company

FoundedEmployeesCEOWebsite
200050Bernard Courtieuhttps://integragen.com

IntegraGen SA provides human genome analysis services for academic researcher and life sciences companies in France. Its genomic services include transcriptomics, epigenomics, DNA sequencing, NGS testing for cancer research, and SNP genotyping. The company offers clinical research services, such as clinical grade sequencing and pharmacogenomics; basic and human genetic research; agrigenomic services, including crop and livestock genotyping and high-throughput sequencing for crops and livestock; and microbial genomics services comprising whole-genome microbial sequencing and microbial transcriptomics.

IntegraGen Fundamentals Summary

How do IntegraGen's earnings and revenue compare to its market cap?
ALINT fundamental statistics
Market Cap€7.26m
Earnings (TTM)€15.00k
Revenue (TTM)€11.32m

482.3x

P/E Ratio

0.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALINT income statement (TTM)
Revenue€11.32m
Cost of Revenue€0
Gross Profit€11.32m
Other Expenses€11.31m
Earnings€15.00k

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

Oct 18, 2022

Earnings per share (EPS)0.0023
Gross Margin100.00%
Net Profit Margin0.13%
Debt/Equity Ratio89.3%

How did ALINT perform over the long term?

See historical performance and comparison

Valuation

Is IntegraGen undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


482.3x

Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ALINT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ALINT's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: ALINT is poor value based on its Price-To-Earnings Ratio (482.3x) compared to the European Biotechs industry average (37.2x).

PE vs Market: ALINT is poor value based on its Price-To-Earnings Ratio (482.3x) compared to the French market (16.2x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALINT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ALINT is overvalued based on its Price-To-Book Ratio (3.3x) compared to the FR Biotechs industry average (2.8x).


Future Growth

How is IntegraGen forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


48.6%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as IntegraGen has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has IntegraGen performed over the past 5 years?

Past Performance Score

3/6

Past Performance Score 3/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


33.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ALINT has high quality earnings.

Growing Profit Margin: ALINT became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: ALINT has become profitable over the past 5 years, growing earnings by 33.1% per year.

Accelerating Growth: ALINT has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: ALINT has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).


Return on Equity

High ROE: ALINT's Return on Equity (0.7%) is considered low.


Financial Health

How is IntegraGen's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: ALINT's short term assets (€9.0M) exceed its short term liabilities (€5.5M).

Long Term Liabilities: ALINT's short term assets (€9.0M) exceed its long term liabilities (€2.0M).


Debt to Equity History and Analysis

Debt Level: ALINT has more cash than its total debt.

Reducing Debt: ALINT's debt to equity ratio has reduced from 112.7% to 89.3% over the past 5 years.

Debt Coverage: Insufficient data to determine if ALINT's debt is well covered by operating cash flow.

Interest Coverage: Insufficient data to determine if ALINT's interest payments on its debt are well covered by EBIT.


Balance Sheet


Dividend

What is IntegraGen current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALINT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALINT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALINT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALINT's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ALINT has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

15.3yrs

Average management tenure


CEO

Bernard Courtieu

14.67yrs

Tenure

€235,171

Compensation

Dr. Bernard Courtieu, DVM, MBA, has been the Chief Executive Officer of OncoDNA SA since January 2021. Dr. Courtieu serves as the Chief Executive Officer of IntegraGen S.A. since September 2007 and also se...


Leadership Team

Experienced Management: ALINT's management team is seasoned and experienced (15.3 years average tenure).


Board Members

Experienced Board: ALINT's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

IntegraGen SA's employee growth, exchange listings and data sources


Key Information

  • Name: IntegraGen SA
  • Ticker: ALINT
  • Exchange: ENXTPA
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: €7.262m
  • Shares outstanding: 6.63m
  • Website: https://integragen.com

Number of Employees


Location

  • IntegraGen SA
  • Genopole Campus 1 – Bât. 8
  • 5, Rue de Henri Desbruères
  • Évry
  • Ile-de-France
  • 91000
  • France

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/27 00:00
End of Day Share Price2022/05/27 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.